Endocrine Abstracts

Introduction: Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common conditions that regularly coexist and can act synergistically to drive adverse outcomes. The prevalence of NAFLD in T2DM is 70%, with 16% having evidence of advanced hepatic fibrosis.Aims: Our study therefore had two aims: Firstly, to define the attitudes and current clinical practice of diabetes specialists towards NAFLD across the UK and secondly, to implement...

Objective: 2–3% of the population of the UK receive glucocorticoid (GC) therapy. Significant adverse effects are not confined to chronic use: recurrent short-course administration is associated with increased morbidity and mortality. Data about the cumulative dose responsible for drawbacks during GC treatment are still lacking. The aim of this study was to test the impact of 7 days of 10 or 15 mg of Prednisolone on metabolism in healthy male volunteers.<p class="abste...

Objective: Currently, 2–3% of the population of the UK and US receive glucocorticoid (GC) therapy. Significant adverse effects are not confined to chronic use; recurrent short-course administration is associated with increased morbidity and mortality. The efficacy of GC therapy is not in doubt but data about the cumulative dose responsible for adverse effects during GC treatment are still lacking. The aim of this study was to test the impact of 7 days of 10 or 15 mg of Pr...

Introduction: The relationship between non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes is well-established. However, the precise impact of glucose control on the severity and progression of NAFLD remains largely unexplored. Currently, none of the non-invasive scoring systems used to assess NAFLD severity incorporate glucose control markers, such as glycated hemoglobin (HbA1c).Methods: Data were collected fr...